A Phase 1 Trial to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of VIS171 in Participants With Autoimmune Disease(s)

Clinical trial NCT06799520 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06799520
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Systemic Lupus Erythematosus (SLE)Alopecia Areata (AA)Immune-mediated Focal Segmental Glomerulosclerosis (FSGS)

Start date: 2025-03-17
Primary completion: 2026-10-19
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.